Sanofi Consumer Healthcare India Ltd (NSE: SANOFICONR, BSE: 544250) is a Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹8,173 Cr, it ranks #659 by market cap among the 6,137 Indian listed companies on FinBizNet, and #13 of 63 in Pharmaceuticals. At ₹3,207.90 (as of 25 Oct 2026), the share price is 39.0% below its 52-week high of ₹5,255.00 and 0.2% above its 52-week low of ₹3,200.00. The share price is down 32.0% over one year and down 31.4% over three months.
| Current Price | ₹3,207.90 |
|---|---|
| Market Cap | ₹8,173 Cr |
| NSE Symbol | SANOFICONR |
| BSE Code | 544250 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 33.4 |
| Return on Equity | 73.09% |
| Return on Assets | 37.99% |
| 52-Week Range | ₹3,200.00 – ₹5,255.00 |
| 1-Year Price Change | -32.0% |
| 3-Month Price Change | -31.4% |
| Beta (1Y) | 0.23 |
| Dividend Yield | 2.16% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.sanofi.com/en/Consumer-Healthcare/health-and-well-being |
| Revenue | ₹236 Cr |
|---|---|
| Net Profit | ₹69 Cr |
| Net Margin | 29.2% |
| EPS (Basic) | ₹29.87 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Sanofi Consumer Healthcare India Limited operates as a fast-moving consumer healthcare company in India. It offers products in the allergy, physical wellness, and pain care segments under brands, such as Allegra, Combiflam, Avil, DePURA, Festal, and Novalgin NU through distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains, and e-commerce. The company was incorporated in 2023 and is based in Mumbai, India. Sanofi Consumer Healthcare India Limited is a subsidiary of Opella Healthcare Participations B.V.
1. Pharmaceutical Business-This segment engages in pharmaceutical business. 2. No Operations-NA 3. NA-NA 4. NA-NA
1. Pharmaceutical Business-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Sanofi Consumer Healthcare India Ltd | ₹8,173 Cr | 33.4 | 73.09% | ₹236 Cr | -32.0% |
Listed by market capitalisation. Ratios are shown for context only.
Sanofi Consumer Healthcare India Ltd is trading at ₹3,207.90, with a market capitalisation of ₹8,173 Cr.
Sanofi Consumer Healthcare India Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Sanofi Consumer Healthcare India Ltd has a P/E of 33.4 and a return on equity of 73.09%.
Sanofi Consumer Healthcare India Ltd is listed on the NSE under the symbol SANOFICONR and on the BSE under the scrip code 544250.
Sanofi Consumer Healthcare India Ltd's share price is down 32.0% over one year and down 31.4% over three months. Its 52-week range is ₹3,200.00 to ₹5,255.00.
In Q1 FY27, Sanofi Consumer Healthcare India Ltd reported revenue of ₹236 Cr and net profit of ₹69 Cr, with basic EPS of ₹29.87 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.